arrow
R

Reuben Benjamin

assistance publique hopitaux paris (aphp)
H指数:31
被引数:4,532

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma-2-year follow-up (final analysis)

Locomotion: 对复发/难治性多发性骨髓瘤的三重暴露患者的现实生活中当前护理标准的研究-2年随访 (最终分析)

LEUKEMIA
IF13.4
2024-09-250
OAAI
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
2023-07-0321
OAAI
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide- dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2 non-inferiority trial
2023-02-0113
OAAI
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

UCART19,一流的同种异体anti-CD19嵌合抗原受体T细胞疗法,用于成人复发或难治性b细胞急性淋巴细胞白血病 (CALM): 1期,剂量递增试验

2022-11-0162
PRE
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Locomotion: 一项前瞻性,非干预性,跨国研究,对复发和/或难治性多发性骨髓瘤患者的现实生活现行护理标准

LEUKEMIA
IF13.4
2022-03-24128
OAAI
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma
2022-01-1145
OAAI
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
2021-12-299
OA
Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London
2021-08-1639
OAAI
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone
2021-07-125
OAAI
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
2021-07-0518
OAAI
Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma
LEUKEMIA
IF13.4
2021-06-1816
OAAI
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
2021-05-0315
OAAI
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
2021-04-1314
OAAI
Proceedings From the First International Workshop at Sidra Medicine: Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development, 15th-16th February 2019, Doha, Qatar

Sidra Medicine第一届国际研讨会论文集: 癌症免疫治疗中的工程免疫细胞 (EICCI): 从发现到现成的开发,2019年2月15-16日,卡塔尔多哈

2021-01-140
OAAI
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

基因组编辑,供体来源的同种异体anti-CD19嵌合抗原受体T细胞在儿童和成人b细胞急性淋巴细胞白血病中的应用: 两项1期研究的结果

LANCET
IF88.5
2020-12-01244
PREAI